Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition

What Was Tested

This randomized controlled trial paper looks at Teduglutide (GLP-2 analog).

To measure effects of a GLP-2 agonist, teduglutide (TED), compared with placebo (PLA) on gastric emptying (GE), overall gut transit, fluid balance, intestinal monosaccharide absorption, and permeability in patients with SBS on home PN (HPN).

Why It Was Studied

Other mechanisms may also play a role in effects of GLP-2 agonists.

Who Took Part

According to the abstract, 8 adults were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled, crossover and pilot.

The adults were allocated by chance, so the Teduglutide (GLP-2 analog) group and the comparison group should start out alike.

As a double-blind Teduglutide (GLP-2 analog) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Teduglutide (GLP-2 analog) could be set against what happens without it.

In the crossover set-up each of the adults took both Teduglutide (GLP-2 analog) and the comparison in turn, acting as their own control.

Analysis used the paired t test.

What Was Measured

PubMed files the paper under topics including Citrulline, Gastric Emptying, Gastrointestinal Tract, Glucagon-Like Peptide 2, Intestinal Absorption, Lactulose and Mannitol.

The authors tagged it with the keywords GLP2, gastrointestinal transit, permeability, short bowel syndrome and teduglutide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teduglutide (GLP-2 analog) in 8 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (JPEN. Journal of parenteral and enteral nutrition), a journal based in United States.

More context: the Teduglutide (GLP-2 analog) compound page.